D'Haens, G., Danese, S., Panaccione, R., Rubin, D. T., Peyrin-Biroulet, L., Matsuoka, K., . . . Schreiber, S. (2025). Deucravacitinib in patients with inflammatory bowel disease: 12-week efficacy and safety results from 3 randomized phase 2 studies in Crohn's disease and ulcerative colitis. Journal of Crohn's & Colitis, 19(6), 1. https://doi.org/10.1093/ecco-jcc/jjaf080
Chicago Style (17th ed.) CitationD'Haens, Geert, et al. "Deucravacitinib in Patients with Inflammatory Bowel Disease: 12-week Efficacy and Safety Results from 3 Randomized Phase 2 Studies in Crohn's Disease and Ulcerative Colitis." Journal of Crohn's & Colitis 19, no. 6 (2025): 1. https://doi.org/10.1093/ecco-jcc/jjaf080.
MLA (9th ed.) CitationD'Haens, Geert, et al. "Deucravacitinib in Patients with Inflammatory Bowel Disease: 12-week Efficacy and Safety Results from 3 Randomized Phase 2 Studies in Crohn's Disease and Ulcerative Colitis." Journal of Crohn's & Colitis, vol. 19, no. 6, 2025, p. 1, https://doi.org/10.1093/ecco-jcc/jjaf080.
